-+ 0.00%
-+ 0.00%
-+ 0.00%
Cellution Biologics Inc. Signs Definitive Agreement to Acquire SimpliDerm® Human Hydrated Acellular Dermal Matrix Business from Elutia Inc., Expanding its Allograft Portfolio
Share
Listen to the news

ROSWELL, Ga., July 16, 2026 (GLOBE NEWSWIRE) -- Cellution Biologics Inc., a biologics company focused on developing, manufacturing, and commercializing advanced human tissue-based products for wound care, ocular repair, and other surgical applications, today announced that it has signed a definitive agreement to acquire the SimpliDerm® hydrated human acellular dermal matrix ("ADM") business from Elutia Inc.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending